SLC5A2 and hydrops fetalis: The EMPA-RESPONSE-AHF study (7) highlighted the safety and potential benefits of the early use of SGLT2 inhibitors in patients with AHF, which reduced the combined endpoint of HF exacerbation, HF rehospitalization, or 60-day death but did not affect diuretic response in patients with AHF.